- Home
- SRFM vs TLSA Comparison
SRFM vs TLSA Comparison
Compare SRFM & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- TLSA
- Stock Information
- Founded
- SRFM 2011
- TLSA 2013
- Country
- SRFM United States
- TLSA United Kingdom
- Employees
- SRFM N/A
- TLSA N/A
- Industry
- SRFM Transportation Services
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- TLSA Health Care
- Exchange
- SRFM Nasdaq
- TLSA Nasdaq
- Market Cap
- SRFM 185.9M
- TLSA 187.0M
- IPO Year
- SRFM 2023
- TLSA 2000
- Fundamental
- Price
- SRFM $4.53
- TLSA $1.78
- Analyst Decision
- SRFM Buy
- TLSA
- Analyst Count
- SRFM 4
- TLSA 0
- Target Price
- SRFM $5.75
- TLSA N/A
- AVG Volume (30 Days)
- SRFM 1.7M
- TLSA 330.7K
- Earning Date
- SRFM 11-13-2025
- TLSA 05-06-2025
- Dividend Yield
- SRFM N/A
- TLSA N/A
- EPS Growth
- SRFM N/A
- TLSA N/A
- EPS
- SRFM N/A
- TLSA N/A
- Revenue
- SRFM $107,372,000.00
- TLSA N/A
- Revenue This Year
- SRFM N/A
- TLSA N/A
- Revenue Next Year
- SRFM $18.06
- TLSA N/A
- P/E Ratio
- SRFM N/A
- TLSA N/A
- Revenue Growth
- SRFM N/A
- TLSA N/A
- 52 Week Low
- SRFM $1.10
- TLSA $0.63
- 52 Week High
- SRFM $9.91
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- SRFM 54.30
- TLSA 49.08
- Support Level
- SRFM $4.13
- TLSA $1.63
- Resistance Level
- SRFM $4.57
- TLSA $1.88
- Average True Range (ATR)
- SRFM 0.27
- TLSA 0.16
- MACD
- SRFM 0.04
- TLSA -0.00
- Stochastic Oscillator
- SRFM 84.88
- TLSA 69.23
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.